Search

Antihemophilic factor (recombinant), PEGylated

PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

Benzyl alcohol

Benfluorex

The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. … This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.

Polysorbate 20

It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions. … Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications.

Pyruvic acid

(From Stedman, 26th ed) … An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

Trimethadione

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Cholecystokinin

This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.

rsPSMA Vaccine

rsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.

Elasomeran

[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … [L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.

Bromotheophylline

[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113]